Compugen, AstraZeneca’s Ongoing Collaboration Achieves Preclinical Milestone
On December 23rd, Israel-based Compugen, a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, achieved a preclinical milestone in developing bispecific and multi-specific antibody products with AstraZeneca. …
Read More